TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02320565

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopy
Description: 3D Laparoscopy approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Laparoscopy
Description: Standard laparoscopy approach
Study: NCT02925676

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyposafe H02
Description: hypoglycaemia notification device
Study: NCT04629482

Intervention type: OTHER
Intervention: Brain networks activity
Description: The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.

Intervention type: OTHER
Intervention: Brain networks activity
Description: The brain network activity under different conditions will be evaluated by magnetoencephalography, including resting, listen to different types of music, watch different types of videos, and interacting with cognitive stimulation conditions.
Study: NCT00003500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antineoplaston therapy (Atengenal + Astugenal)
Description: Patients with Refractory or Recurrent Intermediate-Grade Stage II - IV Non-Hodgkin's Lymphoma will receive Antineoplaston therapy (Atengenal + Astugenal).~The daily doses of A10 and AS2-1 are divided into six infusions, which are given at 4-hourly intervals. Each infusion starts with infusion of A10 and is immediately followed by infusion of AS2-1.
Study: NCT04616261

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: 6 weeks of training

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Training
Description: 6 weeks of training

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: inhalation of 54 microg formoterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol
Description: inhalation of 54 microg formoterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inhalation of placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: inhalation of placebo
Study: NCT00541450

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: sitagliptin phosphate (sitagliptin)
Description: sitagliptin 100 mg tablet q.d. orally for a 12-wk treatment period

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate (+) metformin hydrochloride
Description: sitagliptin/metformin HCl (Sita/Met) 50/500 mg b.i.d. orally and then 50/1000 mg b.i.d. orally for a 28-wk treatment period

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: pioglitazone
Description: pioglitazone 15 mg tablet q.d. orally for 6 weeks, followed by 30 mg q.d orally for 6 weeks, followed by 45 mg q.d. orally, up to 40 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matching placebo to pioglitazone
Description: matching placebo to pioglitazone tablet q.d. orally, for a 40-wk treatment period.~Participants were administered matching placebo the 15 mg pioglitazone q.d. orally for 6 weeks, followed by matching placebo to 30 mg pioglitazone q.d orally for 6 weeks, followed by matching placebo to 45 mg pioglitazone q.d. orally, up to 40 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching placebo to sitagliptin
Description: matching placebo to sitagliptin q.d., orally for a 12-wk treatment period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Matching Placebo to Sita/Met FDC
Description: matching placebo to Sita/Met FDC - 50/500 mg b.i.d. for 4 weeks and then 50/1000 mg b.i.d. orally for a 28-wk treatment period (Week 12 to Week 40).
Study: NCT01869842

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT-guided percutaneous coronary intervention
Description: the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous coronary intervention
Description: the traditional percutaneous coronary intervention by Resolute zotarolimus-eluting stent insertion

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: OCT-guided percutaneous coronary intervention
Description: the percutaneous coronary intervention using optical coherence tomography by Resolute zotarolimus-eluting stent insertion
Study: NCT02262533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atenolol
Study: NCT03011632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mometasone Nasal
Description: a group of children who will receive a nasal mometasone in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% Sodium chloride (NaCl) solution in a nasal nebuliser once a day for 3 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo mometasone
Description: a group of children without IgE-dependent hypersensitivity who will receive nasal mometasone placebo in an atomiser for three months (one application, once per day) and supplemental 3ml 0.9% NaCl solution in a nasal nebuliser once a day for 3 months,
Study: NCT00137566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: acetaminophen (paracetamol)
Description: Paracetamol tablets, 50 mg/kg/day for 3 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01417689

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Encouragement to attempt eye drop instillation with a specific technique
Description: Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Encouragement to attempt eye drop instillation with a specific technique
Description: Encouragement to one of the 2 techniques (open eyes and closed eyes) is accomplished through a standardized educational session designed to take2-5 minutes.
Study: NCT03909126

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix administered during gestational diabetes screening
Description: Boostrix administered during gestational diabetes screening

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Boostrix administered in high volume obstetric clinic
Description: Boostrix administered in high volume obstetric clinic
Study: NCT04719091

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lubricity
Description: Oral spray

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Lubricity
Description: Oral spray
Study: NCT03076099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: 1.2 μg/kg Dexmedetomidine was administered intravenously constantly after tracheal extubation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: equal volume of normal saline was administered intravenously constantly after tracheal extubation.
Study: NCT02432872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin
Description: defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Daunorubicin
Description: defferent doses of daunorubicin,that is 60mg/m2 for 3 doses compared with 45mg/m2 for 3 doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cytarabine
Description: medium dosage cytarabine（1 g/m2 q12h for 3 days) compared with standard dosage cytarabine(100mg/m2 per day for 6 days)combinated with aclacinomycin（20mg per day for 6 days）for consolidation therapy.
Study: NCT01440426

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous connective tissue graft with rotated papilla flap
Description: Subepithelial connective tissue graft harvested from hard palate

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Collagen matrix construct (Mucograft)
Description: Mucograft Collagen Matrix combined with rotated papilla flap
Study: NCT01012232

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 20 mL ropivacaine 5 mg/mL

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10 mL ropivacaine 10 mg/mL
Study: NCT02953301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: resminostat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02448459

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COOL-COS
Description: Controlled ovarian stimulation will start on the second or third day of a menstrual cycle: Oral clomiphene citrate: 100 mg/day until the day of the triggering. Oral letrozole: 7.5 mg/day during the first 5 days of the controlled ovarian stimulation.~Corifollitropin Alfa: 100 mcg on the 3rd day of the controlled ovarian stimulation.~The triggering will be performed using leuprorelin 1 mg (subcutaneous).
Study: NCT03384745

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1095 (Sonelokimab)
Description: M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1095 (Sonelokimab)
Description: M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1095 (Sonelokimab)
Description: M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: M1095 (Sonelokimab)
Description: M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: M1095 (Sonelokimab)
Description: M1095 (Sonelokimab) is a trivalent monomeric nanobody® that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo contains no active drug.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Secukinumab is a human immunoglobulin G1 (IgG1) monoclonal antibody that selectively binds IL-17A.
Study: NCT01430260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciclesonide
Description: 200 ㎍ once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levocetirizine
Description: 5mg once daily
Study: NCT05297747

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apical periodontitis
Description: Radiography of the patients were taken. Blood samples were collected from those patients.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Chronic periodontitis
Description: Radiography of the patients were taken. Blood samples were collected from those patient
Study: NCT03426930

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: self-evaluation of the Body Mass Index
Description: Evaluation of the Body Mass Index before and after the treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-evaluation of the Body Mass Index
Description: Evaluation of the Body Mass Index before and after the treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-behavioral psychotherapies
Description: Cognitive-behavioral psychotherapies before and after the treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapies
Description: Cognitive-behavioral psychotherapies before and after the treatment
Study: NCT03139214

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Intervention
Study: NCT04217226

Intervention type: DEVICE
Intervention: Perfusion index derived parameters
Description: The PVI and PI will be recorded in the supine position by an anaesthesiologist who was not involved in the further intraoperative monitoring of the patient using Masimo SET (MightySat 9900, Masimo Corporation, Irvine, CA, USA). This device allows bluetooth radio for transfer of parameter data to a smart device. The device will be applied on the index finger of the dominant hand of each patient. It will be applied on the hand that neither contains the venous line nor the blood pressure cuff. Three measurements of PVI and PI on one minute interval will be recorded. We will use the average of these readings.~Dicpleth is defined as the ratio of the height of the dicrotic notch to the height of the systolic peak, measured at end-expiratory time.
Study: NCT01430260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ciclesonide & Levocetirizine
Description: * Omnaris (ciclesonide) 200 ㎍ once daily~* Levocetirizine 5mg once daily
Study: NCT02509728

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: choline supplementation
Description: in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: choline supplementation
Description: in addition to standard nutrition: enteral supplementation with 30mg/kg choline chloride for 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Description: in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DHA supplementation
Description: in addition to standard nutrition: enteral supplementation with 60mg/kg DHA for 10 days

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: standard nutrition
Description: standard nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: standard nutrition
Description: standard nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: standard nutrition
Description: standard nutrition

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: standard nutrition
Description: standard nutrition
Study: NCT04124861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug free, IS monotherapy and GC combined with IS
Description: Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug free, IS monotherapy and GC combined with IS
Description: Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug free, IS monotherapy and GC combined with IS
Description: Follow-up intervals: Every 3 months (3th, 6th, 9th, 12th, 15th, 18th month).
Study: NCT03711773

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Physical Therapy Classes
Description: Three times weekly, these subjects will have one hour group physical therapy sessions with either a physical therapist, physical therapy assistant, or personal trainer. These sessions will be aimed to improve strength and function in a low-impact setting designed specifically for those with joint pain.
Study: NCT04431466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: SOC plus different dosing regimens of Ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: SOC plus different dosing regimens of Ivermectin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivermectin
Description: SOC plus different dosing regimens of Ivermectin
Study: NCT00332293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin Alternative Formulation Ophthalmic Solution 0.5%
Description: 1 drop into the conjunctival sac of both eyes 3 times a day for 3 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin hydrochloride ophthalmic solution 0.5% as base
Description: 1 drop into the conjunctival sac of both eyes 3 times a day for 3 days
Study: NCT00927810

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Study: NCT00751374

Intervention type: DRUG
Group type: OTHER
Intervention: gentamicin
Description: topical gentamicin cream on daily basis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gentamicin cream alternating with mupirocin cream
Description: topical gentamicin cream alternating with mupirocin cream at monthly basis
Study: NCT03238950

Intervention type: OTHER
Group type: OTHER
Intervention: Porcine model
Description: participants to conduct training on porcine model

Intervention type: OTHER
Group type: OTHER
Intervention: Synthetic model
Description: participants to conduct training on synthetic model
Study: NCT00798889

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: Sunitinib dose varies according to the doses allowed in previous protocol. It is given once a day, orally with various schedules depending on the parent protocol
Study: NCT04431466

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard treatment for COVID-19
Study: NCT02200731

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: FAMOS: psychosocial family intervention
Description: The FAMOS intervention consists of a six session manualized psychosocial intervention including videos and tools. Four sessions focus on the parents and two sessions focus on the childhood cancer survivor and its siblings. The intervention is conducted by a psychologist with Cognitive Behavioral Therapy experience
Study: NCT03961789

Intervention type: OTHER
Intervention: patients undergoing opioid replacement therapy
Description: patients undergoing opioid replacement therapy
Study: NCT03253224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium Sulfate
Description: Magnesium group receives magnesium sulfate (50 mg/kg) in 100 mL of normal saline over 15 min during induction of anesthesia, followed by a continuous magnesium sulfate infusion (15 mg/kg/h) until the end of surgery.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline group receives the same volume of normal saline, administered according to the same method as in the magnesium group.
Study: NCT03175770

Intervention type: PROCEDURE
Intervention: transoral radiofrequency Resection in Oropharyngeal Tumor Surgery
Description: Patient of 18 years and older with benign or malign tumor in the oropharynx. The resection is done transorally by radiofrequency
Study: NCT04114734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Park Rx
Description: Participants will be advised to visit a specific park at a specific frequency and duration
Study: NCT03540914

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ACETAZOLAMIDE oral capsule
Description: Administration of 1x125mg acetazolamide in the morning, 2x125mg in the evening, starting 24 hours before departure to 3'100m

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Administration of equally looking placebo capsules in the morning and evening, starting 24 hours before departure to 3'100m
Study: NCT02630134

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: These patients receive the Baeta device and take it home
Study: NCT04884334

Intervention type: DEVICE
Intervention: VAC-Stent®
Description: treatment with the VAC-Stent®
Study: NCT03243669

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Virtual chromoendoscopy
Description: Virtual chromoendoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Virtual chromoendoscopy
Description: Virtual chromoendoscopy

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Virtual chromoendoscopy
Description: Virtual chromoendoscopy
Study: NCT03602417

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flare type stent
Description: Flare type has a wide diameter at proximal portion to prevent stent migration.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional D-type stent
Description: This stent is an original full covered stent to treat malignant colorectal obstruction.
Study: NCT05452655

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multidisciplinary Intensive Rehabilitation
Description: The rehabilitation program will last for 6 consecutive weeks and involves the execution of 30 sessions, 5 days a week lasting 160 '/ day each (80' motor; 40 'cognitive and 40' speech therapy rehabilitation) for 3 days a week and 180'/ day (80 'motor; 60' cognitive and 40 'speech therapy rehabilitation) for 2 days a week. The EXP group will receive 18 sessions (3 times a week) of treadmill (20 min), balance exercises and functional reinforcement (20 min). The remaining motor sessions will be defined based on the patient's therapeutic needs.~The cognitive treatment will be proposed both in traditional mode (3 times a week) and through the support of semi-immersive Virtual Reality Rehabilitation System (VRRS) (2 times/week). The VRRS treatment is structured in 2 sessions per week (60 min) for 6 consecutive weeks.~The speech therapy program will include clinical and instrumental evaluations and innovative techniques will be used for the treatment (biofeedback with Vitalstim).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Muscle-stretching and active mobilization exercises
Description: The control group subjects will undergo a home-based self-treatment program for 40 '/ day for 6 consecutive weeks consisting of muscle-stretching and active mobilization exercises.